Astellas Pharma Inc. (4503.T) JPX

2,140.00

-29.5(-1.36%)

Updated at June 03 12:37PM

Currency In JPY

Key Executives

Name	Title	Pay	Year Born
Naoki Okamura	President, Chief Executive Officer & Director	428M	1962
Katsuyoshi Sugita	Executive Vice President, Chief People Officer & Representative Director	185M	1967
Nobuaki Tanaka	President of Japan Commercial & Senior Corporate Executive	0	N/A
Yoshitsugu Shitaka	Chief Scientific Officer & Senior Managing Executive Officer	0	N/A
Tatjana Dragovic	General Counsel, Chief Ethics & Compliance Officer	0	N/A
Nobue Yasuda	General Manager of Finance & Accounting Department	0	N/A
Jun Kono	Senior Executive Officer & Head of Japan Commercial	0	N/A
Atsushi Kitamura	Senior Executive Officer & Chief Financial Officer	0	N/A
Leticia Delgado-Herrera	Vice President and Rx+ M&D Head	0	N/A
Nobuko Kato	Chief Communications & Investor Relations Officer	0	N/A

Name

Title

Pay

Year Born

Naoki Okamura

President, Chief Executive Officer & Director

428M

1962

Katsuyoshi Sugita

Executive Vice President, Chief People Officer & Representative Director

185M

1967

Nobuaki Tanaka

President of Japan Commercial & Senior Corporate Executive

N/A

Yoshitsugu Shitaka

Chief Scientific Officer & Senior Managing Executive Officer

N/A

Tatjana Dragovic

General Counsel, Chief Ethics & Compliance Officer

N/A

Nobue Yasuda

General Manager of Finance & Accounting Department

N/A

Jun Kono

Senior Executive Officer & Head of Japan Commercial

N/A

Atsushi Kitamura

Senior Executive Officer & Chief Financial Officer

N/A

Leticia Delgado-Herrera

Vice President and Rx+ M&D Head

N/A

Nobuko Kato

Chief Communications & Investor Relations Officer

N/A

Description

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.